- Home
- MCRB vs WGRX Comparison
MCRB vs WGRX Comparison
Compare MCRB & WGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- WGRX
- Stock Information
- Founded
- MCRB 2010
- WGRX 2022
- Country
- MCRB United States
- WGRX United States
- Employees
- MCRB N/A
- WGRX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- WGRX Other Pharmaceuticals
- Sector
- MCRB Health Care
- WGRX Health Care
- Exchange
- MCRB Nasdaq
- WGRX Nasdaq
- Market Cap
- MCRB 141.9M
- WGRX 140.2M
- IPO Year
- MCRB 2015
- WGRX 2025
- Fundamental
- Price
- MCRB $0.37
- WGRX $3.29
- Analyst Decision
- MCRB Hold
- WGRX
- Analyst Count
- MCRB 5
- WGRX 0
- Target Price
- MCRB $4.00
- WGRX N/A
- AVG Volume (30 Days)
- MCRB 1.3M
- WGRX 219.8K
- Earning Date
- MCRB 05-07-2025
- WGRX 01-01-0001
- Dividend Yield
- MCRB N/A
- WGRX N/A
- EPS Growth
- MCRB N/A
- WGRX N/A
- EPS
- MCRB 0.00
- WGRX N/A
- Revenue
- MCRB N/A
- WGRX $18,128,831.00
- Revenue This Year
- MCRB N/A
- WGRX N/A
- Revenue Next Year
- MCRB N/A
- WGRX N/A
- P/E Ratio
- MCRB $474.36
- WGRX N/A
- Revenue Growth
- MCRB N/A
- WGRX N/A
- 52 Week Low
- MCRB $0.46
- WGRX $2.32
- 52 Week High
- MCRB $1.53
- WGRX $5.69
- Technical
- Relative Strength Index (RSI)
- MCRB 28.34
- WGRX N/A
- Support Level
- MCRB $0.36
- WGRX N/A
- Resistance Level
- MCRB $0.67
- WGRX N/A
- Average True Range (ATR)
- MCRB 0.07
- WGRX 0.00
- MACD
- MCRB -0.02
- WGRX 0.00
- Stochastic Oscillator
- MCRB 2.71
- WGRX 0.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.